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1. Overview
Until relatively recently, the field of drug design and development was disconnected
from advances in computing and informatics. Without even considering the concept of
computing, previous generations of scientists and clinicians had great motivation to examine
the symptoms of ill or injured patients, infer from sufficient observation data about the causes
of their symptoms, and search for chemical remedies that could cure or somewhat allieviate a
person’s ailment. Today, remedies come from sources such as herbal medicines, a high-quality
nutritional diet, or human-designed medicines developed in research laboratories.
However, there are a great number of afflictions where existing natural remedies are
insufficient, and intervention using computation can be beneficial. Around the same time the
central dogma of molecular biology was proposed in the 1950s, computing technology was
being born in vacuum tubes. For the next 10 years, molecular biology and computing each
advanced in their own spectacular ways, yet applying computing to problems in molecular
biology was still a novelty.
By the end of the 1960s, computing had reached a stage mature enough to be applicable
to biochemical problems of limited scope, and the first generation of bioinformatics and
chemoinformatics was born. Continuing into the next decade, evolutionary trees were
one bioinformatics topic (Waterman et al., 1977), and chemoinformatics topics such as the
efficient representation of chemicals for searchable databases were explored (Wipke & Dyott,
1974). Computing technology was slowly becoming a useful tool to explore the theoretical
underpinnings of the information representing the mechanisms of life.
Both bioinformatics and chemoinformatics have emerged independently in parallel (Jacoby,
2011), much like computing and molecular biology did at first. Their synergy was largely
ignored, not for lack of interest, but rather because the computing power necessary to examine
and solve large chemical biology problems that impact drug design was still insufficient.
(Note the difference between biochemistry, which is biology-centric and focuses on molecule
function, versus chemical biology, which focuses on chemical compounds and their biological
effects.) Furthermore, from the perspective of pharmaceutical companies, why would they
need to consider changing the laboratory techniques which founded their industry in the
first place? Fast forward from the 1970s to the present. Over the past decade computing
technology has and continues to become cheaper, to the point where it is now possible to
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equip individual researchers with multi-processor computing workstations that can compute
systems applicable to drug design and optimization in a realistic amount of time.
With the recent boost in computing power, the era has come where clinicians, wet-lab
scientists, and informaticians can collaborate in inter-disciplinary research for the
advancement of drug design to improve the quality of life. Clinicians provide tissue samples
of patients exhibiting particular symptoms, bench scientists observe tissue behavior and
identify critical molecules of interest, and informaticians provide ways to extract information
from the tissue sample that can be useful in retroactively understanding the mechanismwhich
brought about the symptoms. However, the power of informatics is not only in its retrospective
analysis capability. Depending on the illness or condition under investigation, the objective of
a collaborative research project will be for design of a new pharmaceutical, either a retro-active
drug (suppress a symptom after it has come about) or a pro-active drug (suppress a symptom
before it has come about). Such design is now appreciably impacted by informatics because
of the scale of data and precision required for proper understanding of a phenomenon.
In this chapter, we provide several examples of this collaborative drug design process that
incorporates informatics for chemical biology and their translational experimental impact.
To begin, we review some of the previous methods in which pharmaceuticals have been
developed and analyzed in-silico. Next, we focus on a recent public database that represents
one effort to unify the bioinformatic and chemoinformatic aspects needed for analysis of a
major class of proteins that are drug targets. Our attention then shifts to how to mine this
information in a useful way and uncover new knowledge that can be and is infact tested at
a lab bench. Finally, we provide a glimpse into ongoing research in algorithms that can be
incorporated into existing interaction analysis methods, with the end goal of boosting the
performance of virtual pharmaceutical design beyond what has been achieved thus far.
2. In-silico development of pharmaceuticals
2.1 Pharmacology basics
In pharmacology, two fundamental molecules in biochemical reactions are target proteins,
and chemical compounds that attach to proteins, often called ligands. When a ligand binds to
its target, it triggers a cascade of signals such as a transfer of small groups of atoms or physical
modification of receptor structure. The signal transduction affects how a cell, and ultimately a
living organism, functions. Therefore, the larger question in modern in-silico pharmacological
research is how to construct models which accurately correlate experimental observations
and protein-ligand information to activity, and therefore provide a way to prospectively
(computationally) evaluate the potential efficacy of a newly-designed drug molecule.
2.2 A brief survey of existing virtual screening methods
Virtual screening (VS) is the process of evaluating a library of compounds using a
computational model in order to rank, and thus screen for, molecules that exhibit desired
characteristics. For pharmaceuticals, the main characteristic is its bioactivity or efficacy, which
is the amount of a compound needed to trigger a desired physiological effect, typically in
at least half of the target. For drugs to be advanced beyond a laboratory experiment stage,
bioactivity with micromolar (µM) activity is minimally required, though nanomolar (nM)
activity is often a criterion used by pharmaceutical companies to be considered for advanced
clinical trials necessary for final product approval before manufacturing and distribution.
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The reason why VS is important is simple - the size of chemical space is estimated to be on
the order of 1060 (Dobson, 2004), and therefore it is economically and logistically unrealistic
to perform assays (bioactivity tests) for every chemical compound with every protein in a
biological system. Estimates for the current development costs of a single drug molecule to
reach the market are close to USD $500,000,000. How to explore the enormous chemical space
and reduce such development cost is an open topic addressed to some degree in this chapter.
To date, twomajor classes of VSmethods have been created. The first is structure-based virtual
screening (SBVS). In SBVS, biophysical and phyisochemical models are applied to estimate
binding energies of ligands with a target protein, and the most energy-favorable compounds
can be interpreted as the ligands most likely to exhibit bioactivity. A key requirement of SBVS
methods is that they require knowledge of a target protein. As long as the three-dimensional
structure of the target is known, SBVS can be useful, since molecular shape complementarity
and physical properties important for specific binding can be utilized (Schneider & Fechner,
2005). SBVS was a contributor to the development of the first generation of cyclic urea HIV
protease inhibitor drugs (Lam et al., 1994). Most SBVS approaches include the use of force
fields, a topic that will be discussed later in the chapter.
The second major class of VS methods is ligand-based virtual screening (LBVS). In LBVS, a
set of ligands known to bind to a protein is used to construct a model that correlates ligand
to characteristics to observable properties. Note that for LBVS methods, knowledge about a
target protein is not required. An argument in favor of LBVS is that one can probe and build
hypotheses about an uncharacterized cellular system without knowing any of the proteins
that the cell line contains. LBVS contributed to ligands that effect human T-cell activation
(Schneider & Fechner, 2005).
More thorough surveys of the wealth of SBVS and LBVSmethods created to date can be found
in the literature (Jacoby, 2011; Schneider & Fechner, 2005; Schneider et al., 2009).
2.3 Problems with heterogeneity
Above, we have given a sample of VS algorithms and their contributions to drug design.
However, in most situations, the targets being researched and the target properties used for
evaluation of the VS methodology are different from study to study. Therefore, it is often
difficult to directly compare the ability of different VS studies. It has been estimated that the
ratio of VS approaches to applications is close to one (Schneider, 2010).
The problem of heterogeneity arises from the fact that the goals of past experimental (wet)
researches, and consequently the data available for in-silico method development, were
dependent on the target organism and physiological effect being investigated. For example,
one study may seek the IC50 concentrations of a chemical library which can further vary
based on the assay equipment used, while another study evaluates results using the inhibition
constant Ki. The ICp metric is the concentration required for p% inhibition of a specific cellular
activity. For example, blood clotting drugs for people with hemophilia would be considered
more effective (at clotting) as the IC50 value (inhibition of bleeding activity) becomes smaller.
Being able to reduce IC50 values means having the ability for a drug candidate to be equally
effective at lower concentrations.
How can heterogeneity issues be overcome? One option is to reduce the range of values
possible for a particular metric being used. For a compound library primary screening stage,
one may not need the strength of interactions (change in free energy) or the IC50 concentration
beyond a µM level. Instead, one may simply need a “yes/no”-type of information in order
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to build a hypothesis. In the blood clotting example, we may only need to build a screening
model that predicts if a clotting drug has µM efficacy or better. In the process of drug lead
discovery, “yes/no” is often sufficient, with a numerical value for bioactivity or binding
affinity to be the criterion in the optimization phase.
Here, we provide a few examples of 2-class interaction data useful for drug design research.
The Database of Useful Decoys (DUD) provides over 2000 known ligand-receptor interactions
(Huang et al., 2006). For each interacting ligand, over 30 similar but non-interacting “decoy”
ligands are also provided. Another public database is the NCI anticancer activity dataset,
which logs the bioactivity of thousands of ligands against 60 types of cancer cell lines. For
each cell line, each ligand receives a {+1,−1} label indicating if it does or does not inhibit
the cell line’s growth. The NCI-60 dataset is available from the ChemDB (Chen et al., 2005).
2-class labels will be utilized in Sections 3 and 4, and bioactivity values will be the focus in
Section 5.
2.4 Machine learning
In-silico development of pharmaceuticals is greatly aided by the use of machine learning, an
active research field which develops algorithms to extract statistically meaningful information
from large datasets. The resulting information models can then be applied to clustering,
ranking, or inferfence about unseen data. For those unacquainted with machine learning,
it is easy to think of how a human child learns to distinguish colors or shapes, after which
they can cluster objects of “similar” color or shape together. The concept of similarity is
somewhat of a philosophical argument, and machine learning, much like human learning,
can be adjusted through the definition of “similar”. For drug lead discovery and optimization,
machine learning is the tool that helps us navigate chemical and interaction spaces.
Recently, major contributions to the machine learning field are being achieved through kernel
methods. Kernel methods can be thought of as being comprised of two separate parts
(Shawe-Taylor & Cristianini, 2004): data “recoding” to create patterns representable by linear
functions, and efficient linear pattern analysis algorithms applied to the recoded data. Along
with good theoretical properties, kernel methods have three special features which account
for their recent focus.
First, they can be applied to non-vectorial data that does not have a natural notion of similarity
defined, such as chemical graphs or receptor-ligand interactions. Second, for both vectorial
and non-vectorial data, the calculation of similarity is equivalent to having explicitly mapped
each original data point x ∈ X into a higher, possibly infinite-dimensional feature space F and
using the inner product in F to measure similarity, e.g. a kernel function K(x, y) = φ(x) · φ(y),
for some transformation φ : X → F. This second feature is critical because it represents the
“recoded” similarity value without actually performing the explicit transformation φ. Similarity of
feature vectors that grow exponentially or are infinitesimal in length, and hence are difficult
or otherwise impossible to compute, can still be analyzed via kernel methods as long as
an efficient algorithm to compute the kernel function K : X × X → ℜ exists. Third and
finally, in light of the previous two reasons, kernel functions can replace the inner product
in pattern analysis algorithms. A simple (though uninteresting) kernel function is the basic
inner product K(x, y) = x · y; more interesting kernel functions, more of their properties, and
manipulations on them are abound in the references. The pattern analysis algorithm used in
this chapter is the Support Vector Machine (SVM) (Cristianini & Shawe-Taylor, 2000).
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Machine learning is now widely used in image analysis including facial, text, and license
plate recognition, vital data clustering for clinical applications, and weather and geological
condition prediction. In the remainder of this chapter, we will demonstrate how machine
learning that includes kernel methods is applied to receptor-ligand analyis, inference of novel
protein-ligand binding, and prediction of bioactivity using atomic partial charge information.
3. Bioinformatics and chemoinformatics for GPCR ligand analysis
3.1 GPCR ligands as drug targets
G protein-coupled receptors (GPCRs) are a type of transmembrane receptor found in
eucaryotes. Their physical structure consists of seven transmembrane helices connected
by six extracellular and intracellular loops (EL-{1,2,3}, IL-{1,2,3}). The N-terminus of a
GPCR is extracellular, while the C-terminus is intracellular. Once bonded to by peptide or
small organic ligands, they activate signal transduction pathways inside a cell, and thus,
extracellular ligands which bind to GPCRs affect a cell’s internal downstream signaling.
GPCR ligandsmay be broadly classified into agonists which increase the amount of signalling
that occurs after binding, or antagonists which nullify the effect of agonists and return a cell
to normal signalling levels.
GPCRs are involved in an amazing number of cellular processes, including vision, smell,
mood and behavioral regulation, immune system activity, and automatic nervous system
transmission. It suffices to say that loss of function in GPCRs or regain of function by agonistic
or antagonistic drugs directly affects the health of an organism. The number of GPCRs in the
human genome is more than 1000, with at least 400 of therapeutic interest. In contrast to such
a number of potential therapeutical GPCRs, drugs currently available on the market address
less than 10% of them (Okuno et al., 2008). For a number of GPCRs, the only ligand known
is its endogenous (natural) ligand, and for a considerable number of cases, some GPCRs
are orphaned, meaning that no ligand is known for which binding occurs. This is the entry
point to GPCR in-silico research, requiring a unification of bioinformatics (for GPCRs) and
chemoinformatics (for ligands). Successful design of agonists and antagonists aided by virtual
screening powered through machine learning holds considerable consequence on the future
of pharmaceuticals.
3.2 GPCR-ligand data
The GPCR LIgand DAtabase (GLIDA) represents a major effort in using protein and chemical
similarity informatics techniques independently as well as synergystically (Okuno et al.,
2008). As discussed above, the majority of drugs available on the market address only a small
fraction of GPCRs. The amount of GPCR-ligand interaction space explored is still minimal.
Therefore, exploration of new regions in the interaction space represents the potential for a
number of new GPCR ligands. GLIDA is a database to chart and further navigate such space.
GLIDA utilizes proteome data from the human, mouse, and rat genomes. Drug development
for humans is an obvious motivation, and mouse and rat genomes are selected because
they are frequently used in experimental trials. The interaction data for GLIDA has been
assembled from both public and commercial sources, including DrugBank (Wishart et al.,
2006), PubMed and PubChem (Wheeler et al., 2007), the Ki Database (Roth et al., 2004),
IUPHAR-RD (Foord et al., 2005), and MDL ISIS/Base 2.5.
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The total number of GPCRs in GLIDA is roughly 3700, which has remained stable over the
past five years. What has increased over the lifetime of the GLIDA database is the number of
ligand entries available for analysis and interaction. Since the database’s initial public release
containing 649 compounds, the ligand database has grown to contain over 24,000 agonists
and antagonists. In parallel to the explosion in the number of ligands available, the number
of GPCR-ligand interactions catalogued has also swelled from 2000 to 39,000.
In theory, a naive bioassay system could test the activity of all 3700 ∗ 24000 ∝ 107 GPCR-ligand
pairs. This has at least two disadvantages. First, the exorbitant costs associated with such
an approach are prohibitive. Second, machine learning methods which incrementally use
data from said theoretical assay will encounter problems with model construction in later
phases due to data points which are inconsistent with models of prior generations, and the
computational time cost and efficiency of machine learning when inputting ≥107 data points
is poor. Therefore, the importance of virtual screening is clear.
3.3 Making sense of such quantities of data
With mechanisms in place for storing all of the protein sequences, chemical structures, and
interaction data, the major informatics question is how to extract meaningful information
from the GLIDA database. GLIDA provides a number of analysis services for mining its
information.
First, consider the case when a GPCR has a set of known ligands, and one wishes to search
for other similar GPCRs to see if they share the same target ligands. GLIDA provides two
types of search services for this scenario. First, protein-protein similarity using primary
sequence analysis can be done. For this task, the standard BLAST algorithm is used. The
result of such a search is a collection of proteins which exhibit sequence similarity. GLIDA
also offers an alternative GPCR search strategy that uses gene expression patterns in tissue
origins. In addition to those two services, GPCRs registered in the database are organized
hierarchically using the organization scheme from the GPCRDB project (Horn et al., 2003).
These bioinformatics tools allow an investigator to look for similar GPCRs with increased
efficiency.
Next, consider the second case when a ligand has a target receptor, and one wishes to query
(assay) the same receptor for activity by using similar ligands. In this case, KEGG atom
type (Hattori et al., 2003) frequency profiles are used to represent molecules, and ligands with
similar frequency patterns are returned by a similarity search. The idea that similar frequency
patterns results in similar molecules is based on the concept in linear algebra that vectors
with minimum distance between them in a space have similar component vectors. For this
task, principal component analysis (PCA), a methodology used in bioinformatics as well, is
applied. The database search also provides links to external databases such as PubChem and
DrugBank, allowing users to investigate similarity in other chemical properties provided by
those sources. For example, an investigator may want to evaluate the molecular weight and
number of stereocenters of the 10 ligandsmost similar to the endogenous ligand of a particular
GPCR. GLIDA provides the links to each ligand’s external information, so the user need only
to follow the links provided. Linking multiple chemoinformatics resources makes GLIDA a
useful tool for exploring unknown areas in GPCR-ligand interaction space. Readers interested
in learningmore about clustering of compound libraries can consult additional chapters in this
book.
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Above, we mentioned the idea of assaying a GPCR for similar ligands. A natural question to
ask next is: what about dissimilar ligands? A current and important topic in drug lead design
is scaffold hopping. Scaffold hopping is the occurrence of a pair of ligands which both exhibit
bioactivity for a target protein, but with completely different core structures (scaffolds). The
topic of how data in GLIDA can be used to prospectively evaluate dissimilar ligands for a
GPCR is addressed later in the chapter.
The next tool that GLIDA provides is a visual GPCR-ligand interaction matrix. This is
a graphical version of the GPCR-ligand assay data assembled through bioactivity assay
experiments. It allows one to get a quick visual inspection of the areas in interaction
space which have been explored and remain to be explored. Such interaction maps are
quickly becoming the cornerstone of how to explore interaction spaces in not only GPCRs
but also in many other types of protein classes which can be perturbed. At each cell in the
interaction matrix, three states are possible for a GPCR-ligand pair: (partial or full) known
agonist, (partial or full) known antagonist which in GLIDA includes inverse agonists, or an
unknown/non-interacting state.
The interaction matrix unifies each of the bioinformatics and chemoinformatics algorithms
that GLIDA employs. For a particular cell in the matrix, neighboring columns are the result
of protein similarity calculations. Neighboring rows indicate ligand similarity after applying
the ligand clustering algorithm described above. As a result, the algorithm unification and
resulting visualization gives drug designers key clues for planning future sets of bioactivity
assay experiments and refining drug lead scaffold design.
3.4 Applied examples of GLIDA
The utility of GLIDA can be demonstrated through the following two examples.
In Figure 1, an example interaction matrix is shown. Located between two human alpha
adrenoceptors ADA-1A and ADA-1B lies a similar GPCR named Q96RE8. However, the
ligation status of Q96RE8 is unknown. Looking at the interaction space of neighbors ADA-1A
and ADA-1B, we see that they share a number of common ligands with similar bioactivity.
Therefore, performing laboratory assays of Q96RE8 using the known ligands of similar
proteinswould be expected to discover several novel ligand-receptor pairs. This demonstrates
the power of interactome visualization provided by GLIDA.
Second, let us make a small investigation of a GPCR critical to normal human function. The
dopamine receptor is a type of GPCR involved in a variety of functions, such as the control
of blood pressure and heart rate, certain aspects of visual function, and control of movement
(Strange, 2006). With such a wide variety of behaviors, it is of little surprise that the family of
dopamine receptors (modernly subdivided into five receptors D1-D5) are liganded by many
compounds. Using GLIDA, we first look at the ligands L110 (apomorphine) and L084 (7-OH
DPAT), and notice that they are both agonists. GLIDA provides structural images of the
two compounds as well, shown in Figure 2. Observing the pair, we see that both contain
a hydroxyl (-OH) moiety attached to an aromatic ring. They both also contain a nitrogen atom
with methyl chains attached that is located near or in the rigid ring system. These common
features may be of use in designing new ligands to attach to the dopamine D1 receptor. In
Section 5, we will further discuss atom charges and rigidity of these two ligands.
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Fig. 1. An example of using the GLIDA database to visually inspect the GPCR-ligand
interaction space. The GPCR Q96RE8 is similar to GPCRs ADA-1A and ADA-1B. The
interaction matrix suggests that ligands of ADA-1{AB} may also be ligands of Q96RE8.
4. Unified informatics for prospective drug discovery: chemical genomics
4.1 GLIDA in retrospect
The GLIDA database provides a considerable amount (39,000 pairs) of GPCR-ligand
interaction data. That data is provided by established research resources, such as the KEGG,
IUPHAR, PubChem, and Drugbank databases. The experimental interaction data has been
published in peer-reviewed journals.
The next big step in unifying bioinformatics and chemoinformatics for GPCR ligand discovery
and pharmaceutical development is how to incorporate the information in GLIDA in a
way that can not only analyse data of past trials, but also provide reliable inference of
HO
HO
N
NHO
HBr
Fig. 2. A pair of agonists for the dopamine D1 receptor that contain overlapping
substructures.
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novel GPCR-ligand interaction pairs. We can generalize the situation further by stating the
following goal:
Given a protein-ligand interaction database, build a model which can accurately and
compactly express the patterns existing in interacting complexes (protein-ligand
molecule pairs), and which also has sufficient predictive performance on
experimentally-verifiable novel interactions.
The pharmaceutical motivation behind this next step is the understanding of the mechanisms
of polypharmacology and chemical genomics. Polypharmacology is the phenomenon that
a single ligand can interact with multiple target proteins. Chemical genomics is the other
direction: that a single protein can interact with multiple ligands. Since polypharmacology is
one of the underlying reasons for the side-effects of drugs, and since chemical genomics helps
explain the nature of signalling networks, it is critical to advance our understanding of the
two mechanisms.
In the early days of molecular biology, it was thought that a single protein could be influenced
by a single compound, much like a unique key for a specific lock. Of course, we know
that a series of locks can have a single master key (e.g., used by hotel cleaning staff), and
that a series of keys can all open a single specific lock (e.g., apartment complex entrance).
Polypharmacology and chemical genomics are the replacement of the 1-to-1 protein-ligand
concept with the analogous ideas of master keys or a generic lock that can be opened by many
keys. Both one ligand binding to multiple receptors (MacDonald et al., 2006) and multiple
ligands binding to the same receptor (Eckert & Bajorath, 2007) have been demonstrated
experimentally. Also, a quick look at Figure 1 demonstrates polypharmacology in rows and
chemical genomics in columns of the interactionmatrix. The 1-to-1 concept of binding has had
to be replaced with a systems biology approach that considers interaction space as a network
of nodes and edges, where nodes are proteins and their ligands, and bonds are drawn between
nodes when two molecules interact (bond). What makes informatics special is the ability to
incorporate both polypharmacology and chemical genomics.
Recent advances in high-throughput screening have created an enormous amount of
interaction data. Facilities such as the NIH’s Chemical Genomics Center employ automation
technologies that let researchers test thousands of ligands at various concentrations on
multiple cell types. This non-linear explosion of interaction information requires new
methods formining of the resulting data. Additionally, to becomemore economically efficient,
it is important to reduce the numbers of ligands being tested at facilities like the CGC to those
which are more likely to interact with the target proteins of a specific cell type. This new type
of virtual screening has been termed Chemical Genomics-Based Virtual Screening (CGBVS).
4.2 Reasoning behind Chemical Genomics-Based VS
The interaction matrix provided in the GLIDA database is precisely the motivation for
development of CGBVS techniques. Earlier in the chapter, some of the merits of LBVS and
SBVS were discussed. However, the two methodologies, which have been the principle VS
methods of drug lead design research to this point, have their own drawbacks as well, which
we discuss here.
Since the LBVS methods use no information about the target protein, the ability to investigate
the network of polypharmacology is hampered. For example, let us assume we have ligand
dataset L1 that uses IC50 values based on bioactivity assays with receptor R1, and dataset L2
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uses cell count valuesmeasured after ligation to R2 ( = R1). LBVSmodels built using L1 cannot
be applied to screen L2, because the models have been constructed under the assumption
that R1 was the target. Evaluating L2 on the basis of the LBVS model contstructed using L1
is proverbially “comparing apples to oranges”. The same argument applies for testing L1
using a LBVS model built from L2. One of the other known issues, especially with graph
kernel-based LBVS (see Section 5.2), is that both cross-validated training performance and
prediction performance on unseen ligands containing scaffold hopping are poor. Graph kernel
QSARs (Brown et al., 2010), a type of LBVS methodology, have depended on the frequency of
common topology patterns in order to derive their models, which hence rank non-similar
scaffolds lower.
The SBVS methods require knowledge of the crystal structure of the target protein, which
means that the problem just mentioned for development via LBVS is not a concern.
Unfortunately, SBVS has its own set of limitations. First, the force fields used in SBVS
techniques are constantly undergoing revision. It has been argued that because force fields
and free energy methods are unreliable, they have contributed little to actual drug lead
development (Schneider et al., 2009). Second, the amount of free parameters present in force
fields and molecular dynamics simulations make them extremely difficult to comprehend and
accurately control. We experienced this firsthand when using these methods to investigate
HIV protease cyclic urea inhibitor drugs. Third, the amount of computation involved in
SBVS methods is enormous, even for small peptide ligands of 5-10 residues. Consequently,
SBVS cannot be applied to large libraries such as the 24,000 compounds stored in the GLIDA
database. Last but not least, SBVS is completely unapplicable when the target protein crystal
structure is unavailable, which is frequently the case when a new cold virus or influenza strain
emerges in a population.
Hence, we arrive at the need to create a new generation of informatics algorithms which
overcome the difficulties of LBVS and SBVS. In this section of the chapter, we consider the
development of a first generation CGBVS-style analysis for exploring target-ligand interaction
space. Additionally, the connection between computational chemogenomics (Jacoby, 2011)
and real experimental verification is critical for advancement of in-silico drug lead design.
Also, for the drug lead discovery phase, wewish to search for novel scaffold ligands of a target
protein, rather than explore the amount of lead optimization possible. A graphical depiction
of the various concepts and direction of research is shown in Figure 3. We will return to the
topic of LBVS and its role in drug lead optimization later in the chapter. Though several
research projects have investigated new receptors for existing drugs (polypharmacology),
the work below is the first to perform the opposite (chemical genomics): discovery of new
bioactive scaffold-hopping ligands for existing receptors (Yabuuchi et al., 2011).
4.3 Computational and wet experiments performed
As stated above, an objective of CGBVS is to obtain reliable prediction of ligands previously
unknown to bind to target proteins, and experimentally assay those predictions. In Table 1, a
complete set of dry and wet experiments performed is summarized.
As Table 1 shows, the connection between theory (dry) and reality (wet) is tested extensively.
Critics of informatics argue that its results often do not correlate well with field tests.
However, as Table 1 and Section 4.6 show, such a case study answers such criticisms.
Chemo- and bio-informatics are still in their infancies as established fields of study. One
obvious observation since their inception is the difficulty for informatics labs wishing to field
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Fig. 3. The concepts and objectives of Chemical Genomics-Based Virtual Screening (CGBVS).
test their models. It is hoped that studies such as this one will either encourage laboratories
to engage in both dry and wet research, or will foster increased collaborative efforts between
dry and wet research laboratories.
Type Test Purpose Target Compounds Method
Dry CPI prediction CGBVS vs. LBVS all GPCRs GLIDA cross-validation
Dry
β2AR binding
CGBVS vs. SBVS β2AR (GPCR)
GLIDA
hit rate
Wet CGBVS vs. LBVS/SBVS β2AR binding assay
Dry
β2AR binding
non-GPCR ligand test
β2AR
Bionet
prediction score
Wet cell-based assay
Dry
NPY1R binding NPY1R
prediction score
Wet cell-based assay
Dry CPI prediction CGBVS vs. LBVS/SBVS
EGFR GVK - training
prediction accuracy
CDK2 DUD - test
Wet
EGFR binding
Kinase inhibitor test
EGFR
Bionet - test cell-based assay
CDK2 binding CDK2
Table 1. Summary of dry and wet experiments performed to evaluate the effectiveness of
chemical genomics-based virtual screening (CGBVS). CPI: compound-protein interaction
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4.4 Informatic analysis - methods
In mining interaction data, there are three pieces of information per interaction sample:
the protein sequence, the ligand two-dimensional structure, and whether or not interaction
occurs. The CGBVS strategy employs the SVM pattern analysis algorithm with a kernel
function that uses explicit feature vectors. In this case study, the strength of interaction
is not considered, because the various databases providing the interaction information use
different metrics to indicate interaction, as noted in Section 2.3. Therefore, we must restrict
the interaction domain (the output value) to a binary value. The remaining input to the SVM
is the unification of biological and chemical data.
For proteins in interacting pairs, their sequence data is transformed into a vectorial
representation using the well-known mismatch kernel (see Shawe-Taylor & Cristianini
(2004)), which we will denote by φM(P) for protein sequence P. The mismatch kernel
outputs the frequency of subsequences of fixed length in an input sequence; in particular,
the mismatch kernel can be specified to allow a maximum number of mismatches in the
subsequence being counted. Details of the parameters of the (2,1)-mismatch kernel used for
CGBVS can be found elsewhere (Yabuuchi et al., 2011).
In chemoinformatics, many researches have produced various types of chemical descriptors.
Examples are the Extended Connectivity Fingerprint descriptors, the PubChem descriptors,
and the DragonX descriptors. Each type of descriptor takes a chemical structure as input
and produces a fixed length feature vector that represents characteristics of the molecule.
The characteristics may describe topology patterns, connectivity frequencies, electrostatic
properties, or other measureable types of information. For CGBVS studies, the DragonX
descriptors are employed, which we will denote by φD(L) for ligand L.
If protein-ligand interaction (binding, no binding) is represented by the value i ∈ {B, NB},
then each training data interaction in CGBVS can be represented using the feature vector
FV(P, L, i) = [ φM(P), φD(L), i ] . (1)
Test data simply has one less dimension, since the binding interaction value is unknown.
In experiments, φM(P) is a 400-dimensional vector, and the dimensionality of φD(L) is 929.
Therefore, the SVM builds predictive models using a total of 1330 dimensions.
One of the key differences between LBVS methods and CGBVS methods is the absence of
receptor information in LBVS. The feature vectors for LBVS simply do not have the φ(P)
element.
4.5 Computational experiments
The first computational test done is comparison of CGBVS to existing LBVS. The details of
the LBVS technique used can be found in Yabuuchi et al. (2011). Using the initial release of
interaction data in the GLIDA database (317 GPCRs - 866 ligands - 5207 interactions), 5-fold
cross-validation was repeated multiple times to assess the average predictive performance of
the three techniques. The CGBVS method outperformed LBVS by more than 5%, reaching
more than 90% accuracy in predicting GPCR-ligand interactions. Such results indicate the
extra performance gained by inclusion of the receptor protein in feature vector information.
Next, using the β2-adrenergic receptor (β2AR), a fairly well characterized GPCR with known
crystal structure, retrospective testing of SBVS and CGBVS was done. In this round of testing,
β2AR ligands were available in the GLIDA interaction set, so they were eliminated from the
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training set and used as positive control data. In this test as well, CGBVS provided a higher
enrichment rate than SBVS, meaning more of the highest ranking compounds predicted by
CGBVS were known β2AR ligands than those ranked by SBVS. As opposed to SBVS, CGBVS
considers other protein-ligand interaction, which improves its predictive power.
Having verified CGBVS performance using GLIDA’s data in a retrospective way, the next
test for validating the usefulness of CGBVS was to vary the ligand dataset while holding
the target receptor constant (β2AR). For this purpose, the Bionet chemical library consisting
of 11,500 compounds was used. As no type of cross-validation could be performed for this
library, an alternative measure of “goodness”was used: the aforementioned ability to scaffold
hop. For a number of top-ranking predictions (ligands) experimentally assayed for bioactivity,
scaffold hopping was observed. The same process that was used for testing the Bionet library
against the β2AR receptor was repeated using the neuropeptide Y-type 1 receptor (NPY1R),
with similar successful results.
The next aspect of testing performed was to remove the restriction on the target protein
domain. Instead of GPCRs, protein kinases, molecules whose transfer of phosphate groups
extensively impact cellular signalling, were used as the target protein. A kinase inhibitor
interaction dataset made available by GVK Biosciences was divided into training and test
sets, after which CGBVS, LBVS, and SBVS were trained in the same manner as before.
Kinase-inhibitor interaction prediction accuracy rates again showed that CGBVS was more
effective in mining the interaction space because of its ability to consider multiple interactions
as well as its ability to incorporate both bioinformatic and chemoinformatic aspects into its
interaction complex representation.
4.6 Laboratory assay experiments
For bioinformatics and chemoinformatics to live up to their promise in drug discovery, it
is critical that their predictions be verifiable at the laboratory bench. In this case study for
CGBVS, assay experiments were also performed in order to test computational predictions.
As the focus of this book is on informatics, details of the bioassays will be very brief.
Among the top 50 β2AR prediction scores, those commercially available and not already
identified in the literature as known β2AR ligandswere tested in assays. It is alsoworth noting
that of those ligands that were commercially available, some were known only to be ligands
for different protein domains. This finding provided further evidence of polypharmacology.
Compounds such as granisetron were found to have effective concentration (EC50) values in
the mid-µM range.
For testing the Bionet chemical library with β2AR , 30 compounds were assayed. The power
of CGBVS and informatics to explore interaction space and contribute novel drug leads was
confirmed, as nine of 30 compounds had EC50 or IC50 values in the nM-µM range. Compared
to the hit rates of typical high-throughput screenings where thousands of compounds are
assayed, the hit rate of CGBVS is impressive. Finally, using similar assay techniques, novel
ligands were also found for the EGFR and CDK2 receptors. The structures of novel ligands
and their assay details are published in Yabuuchi et al. (2011).
4.7 Future directions for CGBVS
There are many interesting directions that CGBVS can be continued in.
First, as the amount of ligands available in a chemical library grows, so too does the interaction
space. However, the interaction space is so large that blindly inserting all interactions into a
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machine learning algorithm is inefficient. The development of new techniques to efficiently
sample the interaction space while maintaining the ability to discover novel drug leads
prospectively is a very open topic.
Second, CGBVS has shown that it is successful in identifying ligands that exhibit scaffold
hopping. It therefore reasons that CGBVS can be embedded as part of a ligand generation
algorithm. Development of ligand generation using the Particle Swarm Optimization class of
algorithms is another area of ongoing research (Schneider et al., 2009).
Third, one of the largest hurdles in evaluating protein-ligand interaction prediction techniques
is the availability of non-interacting data. Most scientific journal articles publish results
indicating successful ligand design and interaction strength. However, for the advancement
of in-silico screening techniques, the public availability of datasets of non-interacting pairs is equally
important. In the CGBVS study, non-interacting pairs were defined as randomly selected
protein-ligand pairs not existing in an interaction database. It is easily possible that such
data contains a fraction of false negatives.
5. Boosting CGBVS through improved LBVS methods
5.1 Why return to LBVS?
Earlier in the chapter, we showed how CGBVS outperformed LBVS in terms of target-ligand
interaction prediction performance. Even futher, the predicted interactions were tested in
wet laboratory experiments, and results showed that CGBVS was superior in prospective
interaction studies.
In this final section, we discuss new techniques for optimizing prediction of ligand properties,
such as binding affinity or bioactivity. The techniques fall under the framework of LBVS.
It may seem contradictory that, despite showing the superior performance of CGBVS over
LBVS, we return the discussion to recent advancements in LBVS methods. However, the
motivation for pushing the state of the art in LBVS is at least four-fold:
• There are many cell lines which are completely uncharacterized, and therefore, no
information about receptors and other proteins exists. In this situation, no specific
protein-ligand interaction information is available, but it is still possible to observe and
catalog perturbations to cell lines through the supply of various ligands, and build
predictive models for screening the next generation of ligands to test on the cell line. For
example, such perturbation modeling is useful for deciding on a subsequent selection of
chemical libraries to apply to chemical genomics assays.
• Even in cases where a few target proteins and resulting interactions are known, it may
be an insufficient amount of interaction data to build effective predictors. For example,
one amine receptor and one peptide receptor are hardly enough to characterize the entire
interactome of mice or rats.
• As the CGBVS method used a combination of a protein sequence kernel subsystem and a
chemical descriptor feature vector subsystem, any improvement in the chemical similarity
subsystem can contribute to enhanced CGBVS performance.
• An important distinction exists between the roles of CGBVS and LBVS. The CGBVS process
is responsible for the drug lead screening and discovery process. Once the set of potential
drug molecules to search through has been reduced via CGBVS to the neighborhood of a
12 Systems and Computational Biology – Bioinformatics and Computational Modeling
www.intechopen.com
Unifying Bioinformatics and Chemoinformatics for Drug Design 15
newly discovered drug lead and a target protein, the optimization process can be handed
off to more focused LBVS methodologies.
Given these contexts, it is therefore worth continuing the investigation into new LBVS
methods.
5.2 Graph kernels for target property prediction
Kernel methods feature the convenient property that kernel functions can be designed as
compositions of other kernel functions. Therefore, the CGBVS method can also use any other
chemical kernel function, in combination with or as a replacement for the DragonX descriptors
used in the GPCR, polypharmacology, and chemical genomics studies.
Most LBVS approaches are used to describe Quantative Structure-Activity/Property
Relationships (QSAR/QSPR), which attempt to correlate quantities of ligand structural
features to properties, typically agonistic bioactivity. In recent years, chemical property
prediction via graph topology analysis, a type of QSAR, has received attention. Graph kernel
functions (hereafter “graph kernels”) transform a molecule’s atoms and bonds into respective
graph vertices and edges. Initial researches into graph kernels created a series of random
walks on a chemical graph, in order to explore the topology space of input molecules. The
resulting path frequencies were then used to assess the similarity of chemical structures.
The second generation of graph kernels expanded the type of subgraph being used for kernel
function calculation. Rather than walks on chemical graphs, Mahé and Vert expanded the
subgraph space to use subtrees existing in compound substructures (Mahé & Vert, 2009). For
subtree space T = {t1, t2, . . .}, a weight w(t) that evaluates the amount of subtree branching
and size complexity is assigned to each tree t, and the function ψt(G) counts the frequency of
occurrence of tree-pattern t in a molecular graph. The original subtree graph kernel for two
molecules M1 and M2 is:
K(M1, M2) = ∑
α1,α2∈M1,M2
Kt(tα1 , tα2) , (2)
where αi is an atom in a molecule, and tαi is the subtree rooted at αi. Based on the idea of
convolution kernels, the existing graph kernels have generally been designed for chemical
structures by computing a kernel for trees or paths. In other words, the graph kernels
are defined by incorporating a more fundamental kernel (similarity) KS(s1, s2) between
substructures s1, s2 ∈ S existing inside of graphs. Removing coefficients and constants,
and labelling the chemical graph of molecule Mi as Gi, the graph kernels are essentially
K(G1, G2) = ∑s1,s2∈G1,G2 KS(s1, s2). This (Ks) is precisely the meaning of Kt in the definition
above. The subtrees were found to improve the performance when predicting ligand
anti-cancer activity in multiple types of cell lines using the NCI-60 dataset described in Section
2.3.
A recent third generation of graph kernels next addressed the unresolved problem of chirality
(Brown et al., 2010). The constraints for matching subtrees were extended to enforce matching
atom and bond stereo configurations, meaning the calculation of Kt(t1, t2)was altered to check
for stereochemistry, and performance evaluation using a set of human vitamin D receptor
(hVDR) ligandswith a large number of stereoisomers demonstrated a clear performance boost
in predicting bioactivity. hVDR ligands are being considered as therapeutic drugs because
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of their ability to induce differentiation in leukemia cells and additional ability to suppress
transcription in cells of cancerous tumors.
5.3 State of the art: pushing graph kernels further
Here, we describe a new generation of graph kernels that are being actively researched by the
authors. One of the key drawbacks with existing graph kernels being applicable to large scale
drug optimization is that the graph information alone contains no electrostatic information
which is essential for optimizing protein-ligand binding. Molecular dynamics simulations
and docking programs often make large use of electrostatics in order to estimate binding
free energies and other properties; however, we have stated above that such programs are
unfeasible for scanning large chemical libraries. Another problem with existing graph kernel
QSAR methods is their inability to extract patterns from datasets that contain large amounts
of scaffold hopping. Therefore, a goal in the next generation of graph-based molecule kernel
methods is to incorporate electrostatic information in a two-dimensional graph kernel in
such a way that it can better describe the protein-ligand binding space and more accurately
correlate ligands to their properties.
5.4 The partial charge kernel
5.4.1 Motivations
The partial charge kernel is built using the following motivations:
• Substructures such as esters (-C(C=O)OC-) and thioesters (-C(C=O)SC-) contain the exact
same topology. Therefore, even if graph mismatching similar to the sequence mismatch
kernel used in Section 4 were introduced into existing graph kernel methods in order to
maximize subtree overlap, the distribution of atomic charge would still be different in the
two molecules. A mechanism for capturing this difference in atom charges is important.
For example, consider the figures of GPCR ligands clozapine and chlorpromazine in
Figure 4. They contain structural similarity, but their charge distribution is considerably
different. This difference in information is imporant for the effectiveness of machine
learning algorithms.
• The rigidity of molecules or their substructures directly impact their binding affinity
for a particular receptor. The existing graph kernels do not take rigidity into account.
For example, the structures of apomorphine and 7OH-DPAT shown in Figure 2 are
largely rigid structures, but there is a critical difference in the flexibility of the
methylenes (-CH2-) and methyls (-CH3) attached to the nitrogen atoms. Similarly, the
1,4-methyl-dinitrocyclohexane ring (-NCCN(C)CC) in clozapine (Figure 4) is more rigid
than the antenna (-CCCN(C)(C)) of chlorpromazine.
• Stereochemistry plays a critical role in the efficacy of drug molecules (Lam et al., 1994).
As with the chiral graph kernels recently developed, stereochemistry must be addressed.
Therefore, the partial charge kernel also contains a stereochemistry factor.
• Without sufficient path lengths in graph kernels, identical substituents in remote parts of
molecules anchored off of scaffolds are ignored. In previous studies, the walk and subtree
path lengths considered were typically no more than 6 bonds (7 atoms). However, this
is insufficient for molecules such as steroids typically composed of joined rings, in which
a path length of 6 bonds cannot “see” multiple distant substituents accurately. This is
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Fig. 4. The dopamine D1 and D5 ligands clozapine (left) and chlorpromazine (right), shown
with their structures on top and a distribution of their atomic charges on bottom. The ligands
are agonists for the D5 receptor, but antagonists for the D1 receptor.
also the case when considering a path of length six from the chloride atoms in Figure 4.
Therefore, a molecule partitioning algorithm is formulated into the charge kernels.
5.4.2 Design concepts
We will abbreviate many of the mathematical details of the partial charge kernels being
actively invesigated, and will instead provide descriptions of the concepts that they are meant
to address.
First, since the tree kernels were computationally difficult to apply for tree depths greater than
6 or 7, an initial idea is to apply maximum common substructure (MCS) algorithms to look at
the global maximum overlap and consider the atom-pairwise difference in charges over the
two molecules. This strategy suffers from the idea that core structure substituents in datasets
are highly varied, and the MCSwill therefore erroneously discard these portions of molecules.
Therefore, let us define a componentization function CF(M) that divides a molecule. An
example of a well-known componentization function is the RECAP rule set for retrosynthetic
analysis (Lewell et al., 1998). For experiments in this chapter, CF breaks a molecule into its
ring systems and remaining components. Components consisting of a single hydrogen atom
are eliminated. Label the resulting set of components CF(M) = C = {c1, c2, ...cn}.
The partial charge kernel’s general idea is to evaluate the electrostatic differences in molecule
components. For input molecules M1 and M2, the similarity of components is summed:
KSUMCOMP(M1, M2) = ∑
c1∈CF(M1)
∑
c2∈CF(M2)
KMOL(c1, c2) (3)
Next, we proceedwith the design of themolecule component similarity function KMOL(c1, c2).
The MCS is employed here in two ways. First, it provides the mapping of atoms in one
component to another, such that their difference in atomic charge can be evaluated. Second,
the ratio of the MCS and molecule sizes provides a quick measure of the significance of the
overlap computed. This ratio has a free parameter attached that lets one control how quickly
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to diminish the similarity of molecules based on the difference in their size and MCS. Such a
ratio is a modifying function, m fs(c1, c2), of a more fundamental similarity calculation using
the atom charges.
m fs(c1, c2) =
( 2 ∗ MCSA(c1, c2)
NA(c1) + NA(c2)
)φs
(4)
Finally, the molecule components and their charge distributions will be the information
used to build a fundamental kernel KFK(c1, c2). The partial charge kernel is designed
using convolution through its fundamental kernel KFK(c1, c2), much like the predecessor tree
kernels formulated in equation (2). Though only the size scaling modifier function has been
presented, any number of modifiers providing a multiplicative or additive effect could be
attached to the fundamental kernel. The molecule kernel is thus defined as
KMOL(c1, c2) = m f1 ◦m f2 ◦ . . . ◦m fm(KFK(c1, c2)) . (5)
We will abbreviate the further details of KFK(c1, c2) necessary to incorporate the various
motivations given above. In experimental results below, componentization, stereochemistry,
molecule size ratio, and rigidity are all formulated into KMOL.
5.5 Computational experiment performance
In computational experiments, we evaluate the ability of the partial charge kernels to calculate
the bioactivity of ligands of three different receptors in two different organisms. The first type,
ecdysteroids, are ligands that are necessary for shedding in arthropods. A set of 108 ligands
containing 11 stereoisomer groups was used. The second type of data used is human vitamin
D receptor ligands, whose benefits have been discussed above. Including the endogenous
hVDR ligand, a total of 69 ligands containing 18 stereoisomer groups were used. Finally,
a well known dataset of 31 human steroids which bind to corticosteroid binding globulin
(CBG) is evaluated. The dataset contains two pairs of stereoisomers. More details about all
three datasets can be found in Brown et al. (2010).
For each dataset, the training and testing dataset are randomly divided using a 70%/30% split,
and this randomized split process is repeated five times. First, internal cross-validation tests
are done on the training set. Then, using the entire training dataset (of a particular split), a
predictive model is built, and bioactivity is predicted for each ligand in the split’s test dataset.
To independently evaluate the training set cross-validation and test set prediction
performances, two correlation metrics are used. The training dataset uses the q2 metric:
q2 = 1−
∑(yi − yˆi)
2
∑(yi − y¯)2
, (6)
where yi is sample (compound) i’s known experimental value (activity level or target
property), yˆi is its value output by a predictor during cross-validation, and y¯ is the known
experimental average value. The test dataset uses the R metric:
R =
∑(yi − y¯)(yˆi − ¯ˆy)√
∑(yi − y¯)2 ∑(yˆi − ¯ˆy)2
, (7)
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where ¯ˆy is the average of the predicted values. The maximum values of each of the two
correlation metrics are 1. The correlation metrics can take on negative values as well, which
suggests that a model has poor predictive ability.
To evaluate the partial charge kernels, we consider four criteria:
• q2 ≥ 0, R2 ≥ 0
• q2 ≥ 0.5, R2 ≥ 0
• q2 ≥ 0, R2 ≥ 0.6 (R ≥ 0.774)
• q2 ≥ 0.5, R2 ≥ 0.6
The first criterion is a very simple measure to ensure that a model has some reasonable ability
to correlate molecules to their bioactivities. The second and third criteria are more strict
measures that have been recommended in order for a QSAR model to be applicable to drug
development at an industrial scale. The fourth criterion enforces both the second and third
criteria.
Results of partial charge kernel bioactivity prediction experiments on the human CGB steroids
are highly impressive. Several thousand models satisfied the second requirement of training
data cross-validation performance, and a number of those had R values over 0.85, satisfying
the fourth set of requirements as well. Though the performance is impressive, optimistic
caution must be exercised because the amount of data available is rather small compared to
other datasets. Results on the ecdysteroid dataset, over three times as large as the CGB steroid
dataset, demonstrate the point. Experiments from the ecdysteroid dataset (using random
train-test splits) produce many models with performance that satisfy both the second and
third requirements, but the number of models which satisfy both requirements is limited.
Still, the prediction performances obtained are better than the graph kernels previously
reported. The use of atomic charge information and localized analysis (via componentization
functions) in the kernel function results in prediction improvement. Finally, experiments done
using the hVDR ligand dataset, which contains a rigid core structure, show that accounting
for differences in partial charges and rigidity in components is important for in-silico drug
optimization. For three different hVDR dataset train-test splits tested, partial charge kernel
QSARs built achieve q2 ≥ 0.7 performance. Some of those QSAR models come close to
meeting the fourth criterion, such as a QSAR we could derive with performance (q2 =
0.69, R = 0.745). This is considerably better performance than the chiral graph kernels we
previously developed, which achieved predictions in the range of (q2 = 0.5, R = 0.6).
5.6 Ongoing developments in partial charge kernels
The partial charge kernels have shown improvement in prediction performance over the
basic graph kernels. A number of designs and tests are being planned to bolster prediction
performance.
First is the idea of polarity distribution. If the variance of average component charge is
large, then there are more likely to be multiple sites in the ligand responsible for its activity
and polypharmacology. The distance between components and their average charge must
be correlated somehow. Second, a hybrid of the graph kernels and partial charge kernel
has been proposed. In this kernel function scheme, the graph kernels are employed as in
their original design (Brown et al., 2010), but instead of using a 0/1 value when calculating
the kernel function for a pair of atoms, their difference in charge is used. Finally, as most
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of the individual design concepts used in the partial charge kernel each contain one or
two parameters, investigation of optimal parameter sets which form the pareto optimal is
important in order to bound the number of parameter sets applied to new datasets for
predictive model construction.
In terms of datasets, the hVDR ligands and ecdysteroids provide a nice starting point of
investigating a single particular receptor. By using the known ligands for each GPCR in
the GLIDA database, we can construct a chemical genomics-type of predictive model which
could be applied for screening molecules with optimum bioactivity. Though the hVDR and
ecdysteroid ligands contain a wide variety of bioactivities and structures, the number of
compounds available is relatively small compared to some other databases. In this respect, it
is important to validate the partial charge kernel’s ability to show similarly good performance
on larger data sets.
6. Conclusion
In this chapter, we have considered a number of issues and developments centered
around in-silico design of drug molecules. We demonstrated how the unification of
bioinformatics and chemoinformatics can produce a synergistic effect necessary for themining
of protein-ligand interaction space. Yet, development of algorithms in each of bioinformatics
and chemoinformatics must continue in order to address life science informatics problems of
larger scale. Chemoinformatic algorithm advancement through the partial charge kernels, in
planning for incorporation into the CGBVS framework demonstrated, is an example of such
algorithm advancement. We hope that the survey provided here has provided stimulation to
the reader to investigate and contribute to the complex yet extremely exciting field of in-silico
drug design.
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